#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-4	When	_
1-2	5-8	the	_
1-3	9-14	brain	_
1-4	15-22	changes	_
1-5	23-26	its	_
1-6	27-31	mind	_
1-7	32-33	:	_
1-8	34-45	Oscillatory	_
1-9	46-54	dynamics	_
1-10	55-57	of	_
1-11	58-66	conflict	_
1-12	67-77	processing	_
1-13	78-81	and	_
1-14	82-90	response	_
1-15	91-100	switching	_
1-16	101-103	in	_
1-17	104-105	a	_
1-18	106-113	flanker	_
1-19	114-118	task	_
1-20	119-125	during	_
1-21	126-133	alcohol	_
1-22	134-143	challenge	_
1-23	144-151	Despite	_
1-24	152-155	the	_
1-25	156-166	subjective	_
1-26	167-177	experience	_
1-27	178-180	of	_
1-28	181-186	being	_
1-29	187-189	in	_
1-30	190-194	full	_
1-31	195-198	and	_
1-32	199-209	deliberate	_
1-33	210-217	control	_
1-34	218-220	of	_
1-35	221-224	our	_
1-36	225-232	actions	_
1-37	233-234	,	_
1-38	235-238	our	_
1-39	239-244	daily	_
1-40	245-253	routines	_
1-41	254-258	rely	_
1-42	259-261	on	_
1-43	262-263	a	_
1-44	264-274	continuous	_
1-45	275-278	and	_
1-46	279-290	interactive	_
1-47	291-301	engagement	_
1-48	302-304	of	_
1-49	305-312	sensory	_
1-50	313-323	evaluation	_
1-51	324-327	and	_
1-52	328-336	response	_
1-53	337-348	preparation	_
1-54	349-356	streams	_
1-55	357-358	.	_

2-1	359-363	They	_
2-2	364-370	unfold	_
2-3	371-384	automatically	_
2-4	385-388	and	_
2-5	389-402	unconsciously	_
2-6	403-406	and	_
2-7	407-410	are	_
2-8	411-421	seamlessly	_
2-9	422-432	integrated	_
2-10	433-437	with	_
2-11	438-447	cognitive	_
2-12	448-455	control	_
2-13	456-461	which	_
2-14	462-464	is	_
2-15	465-474	mobilized	_
2-16	475-477	by	_
2-17	478-485	stimuli	_
2-18	486-490	that	_
2-19	491-496	evoke	_
2-20	497-506	ambiguity	_
2-21	507-509	or	_
2-22	510-518	response	_
2-23	519-527	conflict	_
2-24	528-529	.	_

3-1	530-537	Methods	_
3-2	538-542	with	_
3-3	543-547	high	_
3-4	548-563	spatio-temporal	_
3-5	564-575	sensitivity	_
3-6	576-579	are	_
3-7	580-586	needed	_
3-8	587-589	to	_
3-9	590-597	provide	_
3-10	598-605	insight	_
3-11	606-610	into	_
3-12	611-614	the	_
3-13	615-624	interplay	_
3-14	625-632	between	_
3-15	633-642	automatic	_
3-16	643-646	and	_
3-17	647-657	controlled	_
3-18	658-668	processing	_
3-19	669-670	.	_

4-1	671-675	This	_
4-2	676-681	study	_
4-3	682-686	used	_
4-4	687-711	anatomically-constrained	_
4-5	712-715	MEG	_
4-6	716-718	to	_
4-7	719-726	examine	_
4-8	727-730	the	_
4-9	731-741	underlying	_
4-10	742-748	neural	_
4-11	749-757	dynamics	_
4-12	758-760	in	_
4-13	761-762	a	_
4-14	763-770	flanker	_
4-15	771-775	task	_
4-16	776-780	that	_
4-17	781-792	manipulated	_
4-18	793-796	S-R	_
4-19	797-808	incongruity	_
4-20	809-811	at	_
4-21	812-815	the	_
4-22	816-824	stimulus	_
4-23	825-826	(	_
4-24	827-829	SI	_
4-25	830-831	)	_
4-26	832-835	and	_
4-27	836-844	response	_
4-28	845-851	levels	_
4-29	852-853	(	_
4-30	854-856	RI	_
4-31	857-858	)	_
4-32	859-860	.	_

5-1	861-867	Though	_
5-2	868-878	irrelevant	_
5-3	879-880	,	_
5-4	881-889	flankers	_
5-5	890-896	evoked	_
5-6	897-906	automatic	_
5-7	907-918	preparation	_
5-8	919-921	of	_
5-9	922-927	motor	_
5-10	928-933	plans	_
5-11	934-939	which	_
5-12	940-943	had	_
5-13	944-946	to	_
5-14	947-949	be	_
5-15	950-960	suppressed	_
5-16	961-964	and	_
5-17	965-973	reversed	_
5-18	974-983	following	_
5-19	984-987	the	_
5-20	988-994	target	_
5-21	995-1007	presentation	_
5-22	1008-1010	on	_
5-23	1011-1013	RI	_
5-24	1014-1020	trials	_
5-25	1021-1022	.	_

6-1	1023-1036	Event-related	_
6-2	1037-1043	source	_
6-3	1044-1049	power	_
6-4	1050-1059	estimates	_
6-5	1060-1062	in	_
6-6	1063-1067	beta	_
6-7	1068-1069	(	_
6-8	1070-1075	15–25	_
6-9	1076-1078	Hz	_
6-10	1079-1080	)	_
6-11	1081-1090	frequency	_
6-12	1091-1095	band	_
6-13	1096-1098	in	_
6-14	1099-1102	the	_
6-15	1103-1115	sensorimotor	_
6-16	1116-1122	cortex	_
6-17	1123-1130	tracked	_
6-18	1131-1136	motor	_
6-19	1137-1148	preparation	_
6-20	1149-1152	and	_
6-21	1153-1161	response	_
6-22	1162-1164	in	_
6-23	1165-1169	real	_
6-24	1170-1174	time	_
6-25	1175-1178	and	_
6-26	1179-1187	revealed	_
6-27	1188-1197	switching	_
6-28	1198-1202	from	_
6-29	1203-1206	the	_
6-30	1207-1225	incorrectly-primed	_
6-31	1226-1228	to	_
6-32	1229-1232	the	_
6-33	1233-1253	correctly-responding	_
6-34	1254-1264	hemisphere	_
6-35	1265-1266	.	_

7-1	1267-1269	In	_
7-2	1270-1278	contrast	_
7-3	1279-1280	,	_
7-4	1281-1286	theta	_
7-5	1287-1299	oscillations	_
7-6	1300-1301	(	_
7-7	1302-1305	4–7	_
7-8	1306-1308	Hz	_
7-9	1309-1310	)	_
7-10	1311-1315	were	_
7-11	1316-1325	sensitive	_
7-12	1326-1328	to	_
7-13	1329-1332	the	_
7-14	1333-1339	levels	_
7-15	1340-1342	of	_
7-16	1343-1354	incongruity	_
7-17	1355-1357	as	_
7-18	1358-1361	the	_
7-19	1362-1368	medial	_
7-20	1369-1372	and	_
7-21	1373-1386	ventrolateral	_
7-22	1387-1394	frontal	_
7-23	1395-1403	cortices	_
7-24	1404-1408	were	_
7-25	1409-1419	especially	_
7-26	1420-1429	activated	_
7-27	1430-1432	by	_
7-28	1433-1441	response	_
7-29	1442-1450	conflict	_
7-30	1451-1452	.	_

8-1	1453-1458	These	_
8-2	1459-1462	two	_
8-3	1463-1468	areas	_
8-4	1469-1472	are	_
8-5	1473-1476	key	_
8-6	1477-1479	to	_
8-7	1480-1489	cognitive	_
8-8	1490-1497	control	_
8-9	1498-1501	and	_
8-10	1502-1507	their	_
8-11	1508-1518	integrated	_
8-12	1519-1532	contributions	_
8-13	1533-1535	to	_
8-14	1536-1544	response	_
8-15	1545-1555	inhibition	_
8-16	1556-1559	and	_
8-17	1560-1569	switching	_
8-18	1570-1574	were	_
8-19	1575-1583	revealed	_
8-20	1584-1586	by	_
8-21	1587-1599	phase-locked	_
8-22	1600-1615	co-oscillations	_
8-23	1616-1617	.	_

9-1	1618-1623	These	_
9-2	1624-1633	processes	_
9-3	1634-1638	were	_
9-4	1639-1656	pharmacologically	_
9-5	1657-1668	manipulated	_
9-6	1669-1673	with	_
9-7	1674-1675	a	_
9-8	1676-1684	moderate	_
9-9	1685-1692	alcohol	_
9-10	1693-1701	beverage	_
9-11	1702-1704	or	_
9-12	1705-1706	a	_
9-13	1707-1714	placebo	_
9-14	1715-1727	administered	_
9-15	1728-1730	to	_
9-16	1731-1738	healthy	_
9-17	1739-1745	social	_
9-18	1746-1754	drinkers	_
9-19	1755-1756	.	_

10-1	1757-1764	Alcohol	_
10-2	1765-1776	selectively	_
10-3	1777-1786	decreased	_
10-4	1787-1795	accuracy	_
10-5	1796-1798	to	_
10-6	1799-1807	response	_
10-7	1808-1816	conflict	_
10-8	1817-1818	.	_

11-1	1819-1821	It	_
11-2	1822-1830	strongly	_
11-3	1831-1841	attenuated	_
11-4	1842-1847	theta	_
11-5	1848-1860	oscillations	_
11-6	1861-1867	during	_
11-7	1868-1876	decision	_
11-8	1877-1883	making	_
11-9	1884-1887	and	_
11-10	1888-1894	partly	_
11-11	1895-1906	re-sculpted	_
11-12	1907-1915	relative	_
11-13	1916-1929	contributions	_
11-14	1930-1932	of	_
11-15	1933-1936	the	_
11-16	1937-1944	frontal	_
11-17	1945-1952	network	_
11-18	1953-1960	without	_
11-19	1961-1970	affecting	_
11-20	1971-1974	the	_
11-21	1975-1980	motor	_
11-22	1981-1990	switching	_
11-23	1991-1998	process	_
11-24	1999-2008	subserved	_
11-25	2009-2011	by	_
11-26	2012-2016	beta	_
11-27	2017-2021	band	_
11-28	2022-2023	.	_

12-1	2024-2027	Our	_
12-2	2028-2035	results	_
12-3	2036-2044	indicate	_
12-4	2045-2049	that	_
12-5	2050-2055	motor	_
12-6	2056-2067	preparation	_
12-7	2068-2070	is	_
12-8	2071-2080	initiated	_
12-9	2081-2094	automatically	_
12-10	2095-2099	even	_
12-11	2100-2104	when	_
12-12	2105-2122	counterproductive	_
12-13	2123-2126	but	_
12-14	2127-2131	that	_
12-15	2132-2134	it	_
12-16	2135-2137	is	_
12-17	2138-2147	monitored	_
12-18	2148-2151	and	_
12-19	2152-2161	regulated	_
12-20	2162-2164	by	_
12-21	2165-2168	the	_
12-22	2169-2179	prefrontal	_
12-23	2180-2189	cognitive	_
12-24	2190-2197	control	_
12-25	2198-2207	processes	_
12-26	2208-2213	under	_
12-27	2214-2222	conflict	_
12-28	2223-2224	.	_

13-1	2225-2229	They	_
13-2	2230-2237	further	_
13-3	2238-2245	confirm	_
13-4	2246-2250	that	_
13-5	2251-2254	the	_
13-6	2255-2265	regulative	_
13-7	2266-2274	top-down	_
13-8	2275-2284	functions	_
13-9	2285-2288	are	_
13-10	2289-2301	particularly	_
13-11	2302-2312	vulnerable	_
13-12	2313-2315	to	_
13-13	2316-2323	alcohol	_
13-14	2324-2336	intoxication	_
13-15	2337-2338	.	_

14-1	2339-2346	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
14-2	2347-2355	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
14-3	2356-2364	Eighteen	_
14-4	2365-2370	young	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
14-5	2371-2372	,	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
14-6	2373-2380	healthy	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
14-7	2381-2391	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#YoungManiaRatingScale
14-8	2392-2393	(	_
14-9	2394-2396	11	_
14-10	2397-2400	men	_
14-11	2401-2402	,	_
14-12	2403-2407	mean	_
14-13	2408-2409	[	_
14-14	2410-2411	±	_
14-15	2412-2414	SD	_
14-16	2415-2416	]	_
14-17	2417-2420	age	_
14-18	2421-2422	=	_
14-19	2423-2427	25.1	_
14-20	2428-2429	±	_
14-21	2430-2433	3.5	_
14-22	2434-2439	years	_
14-23	2440-2441	,	_
14-24	2442-2447	range	_
14-25	2448-2453	21–34	_
14-26	2454-2459	years	_
14-27	2460-2461	)	_
14-28	2462-2474	participated	_
14-29	2475-2477	in	_
14-30	2478-2482	this	_
14-31	2483-2488	study	_
14-32	2489-2492	and	_
14-33	2493-2502	completed	_
14-34	2503-2506	all	_
14-35	2507-2515	sessions	_
14-36	2516-2518	of	_
14-37	2519-2522	the	_
14-38	2523-2533	experiment	_
14-39	2534-2535	.	_

15-1	2536-2539	All	_
15-2	2540-2552	participants	_
15-3	2553-2557	were	_
15-4	2558-2560	of	_
15-5	2561-2566	legal	_
15-6	2567-2575	drinking	_
15-7	2576-2579	age	_
15-8	2580-2582	in	_
15-9	2583-2586	the	_
15-10	2587-2593	United	_
15-11	2594-2600	States	_
15-12	2601-2602	.	_

16-1	2603-2615	Participants	_
16-2	2616-2620	were	_
16-3	2621-2626	right	_
16-4	2627-2633	handed	_
16-5	2634-2635	,	_
16-6	2636-2647	non-smokers	_
16-7	2648-2651	and	_
16-8	2652-2660	reported	_
16-9	2661-2663	no	_
16-10	2664-2671	medical	_
16-11	2672-2673	,	_
16-12	2674-2682	alcohol-	_
16-13	2683-2685	or	_
16-14	2686-2698	drug-related	_
16-15	2699-2707	problems	_
16-16	2708-2709	;	_
16-17	2710-2712	no	_
16-18	2713-2719	family	_
16-19	2720-2727	history	_
16-20	2728-2730	of	_
16-21	2731-2738	alcohol	_
16-22	2739-2741	or	_
16-23	2742-2746	drug	_
16-24	2747-2752	abuse	_
16-25	2753-2755	in	_
16-26	2756-2761	their	_
16-27	2762-2768	first-	_
16-28	2769-2771	or	_
16-29	2772-2785	second-degree	_
16-30	2786-2795	relatives	_
16-31	2796-2797	;	_
16-32	2798-2800	no	_
16-33	2801-2812	medications	_
16-34	2813-2815	at	_
16-35	2816-2819	the	_
16-36	2820-2824	time	_
16-37	2825-2827	of	_
16-38	2828-2831	the	_
16-39	2832-2837	study	_
16-40	2838-2839	;	_
16-41	2840-2842	no	_
16-42	2843-2851	previous	_
16-43	2852-2865	head-injuries	_
16-44	2866-2867	;	_
16-45	2868-2871	and	_
16-46	2872-2874	no	_
16-47	2875-2878	MRI	_
16-48	2879-2896	contraindications	_
16-49	2897-2898	.	_

17-1	2899-2907	Subjects	_
17-2	2908-2916	reported	_
17-3	2917-2925	drinking	_
17-4	2926-2933	alcohol	_
17-5	2934-2946	occasionally	_
17-6	2947-2948	(	_
17-7	2949-2952	2.0	_
17-8	2953-2954	±	_
17-9	2955-2958	1.1	_
17-10	2959-2964	times	_
17-11	2965-2966	a	_
17-12	2967-2971	week	_
17-13	2972-2973	)	_
17-14	2974-2977	and	_
17-15	2978-2980	in	_
17-16	2981-2996	low-to-moderate	_
17-17	2997-3004	amounts	_
17-18	3005-3006	(	_
17-19	3007-3010	2.7	_
17-20	3011-3012	±	_
17-21	3013-3016	1.1	_
17-22	3017-3023	drinks	_
17-23	3024-3027	per	_
17-24	3028-3036	occasion	_
17-25	3037-3038	)	_
17-26	3039-3041	in	_
17-27	3042-3048	social	_
17-28	3049-3057	settings	_
17-29	3058-3061	and	_
17-30	3062-3065	did	_
17-31	3066-3069	not	_
17-32	3070-3074	have	_
17-33	3075-3093	alcoholism-related	_
17-34	3094-3102	symptoms	_
17-35	3103-3104	.	_

18-1	3105-3112	Written	_
18-2	3113-3121	informed	_
18-3	3122-3129	consent	_
18-4	3130-3133	was	_
18-5	3134-3142	obtained	_
18-6	3143-3147	from	_
18-7	3148-3151	all	_
18-8	3152-3160	subjects	_
18-9	3161-3167	before	_
18-10	3168-3181	participation	_
18-11	3182-3185	and	_
18-12	3186-3194	subjects	_
18-13	3195-3199	were	_
18-14	3200-3210	reimbursed	_
18-15	3211-3214	for	_
18-16	3215-3220	their	_
18-17	3221-3234	participation	_
18-18	3235-3236	.	_

19-1	3237-3240	Two	_
19-2	3241-3251	additional	_
19-3	3252-3257	women	_
19-4	3258-3270	participated	_
19-5	3271-3273	in	_
19-6	3274-3277	the	_
19-7	3278-3283	study	_
19-8	3284-3285	,	_
19-9	3286-3289	but	_
19-10	3290-3295	their	_
19-11	3296-3300	data	_
19-12	3301-3305	were	_
19-13	3306-3315	discarded	_
19-14	3316-3319	due	_
19-15	3320-3322	to	_
19-16	3323-3324	a	_
19-17	3325-3336	substantial	_
19-18	3337-3343	number	_
19-19	3344-3346	of	_
19-20	3347-3352	noisy	_
19-21	3353-3361	channels	_
19-22	3362-3364	in	_
19-23	3365-3368	one	_
19-24	3369-3371	of	_
19-25	3372-3375	the	_
19-26	3376-3379	two	_
19-27	3380-3392	experimental	_
19-28	3393-3401	sessions	_
19-29	3402-3403	.	_

20-1	3404-3408	This	_
20-2	3409-3414	study	_
20-3	3415-3418	was	_
20-4	3419-3427	approved	_
20-5	3428-3430	by	_
20-6	3431-3439	Partners	_
20-7	3440-3445	Human	_
20-8	3446-3454	Research	_
20-9	3455-3478	Committee—Massachusetts	_
20-10	3479-3486	General	_
20-11	3487-3495	Hospital	_
20-12	3496-3497	(	_
20-13	3498-3506	protocol	_
20-14	3507-3513	number	_
20-15	3514-3515	:	_
20-16	3516-3524	P-000181	_
20-17	3525-3526	;	_
20-18	3527-3530	MGH	_
20-19	3531-3532	)	_
20-20	3533-3534	.	_

21-1	3535-3539	Task	_
21-2	3540-3541	A	_
21-3	3542-3547	color	_
21-4	3548-3555	version	_
21-5	3556-3558	of	_
21-6	3559-3566	Eriksen	http://maven.renci.org/NeuroBridge/neurobridge#Triglycerides
21-7	3567-3574	flanker	_
21-8	3575-3579	task	_
21-9	3580-3583	was	_
21-10	3584-3588	used	_
21-11	3589-3591	in	_
21-12	3592-3596	this	_
21-13	3597-3602	study	_
21-14	3603-3604	.	_

22-1	3605-3608	Two	_
22-2	3609-3616	flanker	_
22-3	3617-3624	squares	_
22-4	3625-3627	of	_
22-5	3628-3631	the	_
22-6	3632-3636	same	_
22-7	3637-3642	color	_
22-8	3643-3644	(	_
22-9	3645-3648	red	_
22-10	3649-3650	,	_
22-11	3651-3656	green	_
22-12	3657-3658	,	_
22-13	3659-3663	blue	_
22-14	3664-3665	,	_
22-15	3666-3668	or	_
22-16	3669-3675	yellow	_
22-17	3676-3677	)	_
22-18	3678-3682	were	_
22-19	3683-3692	presented	_
22-20	3693-3695	to	_
22-21	3696-3699	the	_
22-22	3700-3704	left	_
22-23	3705-3708	and	_
22-24	3709-3714	right	_
22-25	3715-3717	of	_
22-26	3718-3721	the	_
22-27	3722-3729	central	_
22-28	3730-3738	location	_
22-29	3739-3742	for	_
22-30	3743-3746	200	_
22-31	3747-3749	ms	_
22-32	3750-3751	(	_
22-33	3752-3755	Fig	_
22-34	3756-3757	1	_
22-35	3758-3759	)	_
22-36	3760-3761	.	_

23-1	3762-3763	A	_
23-2	3764-3770	target	_
23-3	3771-3777	square	_
23-4	3778-3781	was	_
23-5	3782-3791	presented	_
23-6	3792-3799	between	_
23-7	3800-3803	the	_
23-8	3804-3812	flankers	_
23-9	3813-3816	for	_
23-10	3817-3820	200	_
23-11	3821-3823	ms	_
23-12	3824-3825	,	_
23-13	3826-3834	followed	_
23-14	3835-3837	by	_
23-15	3838-3839	a	_
23-16	3840-3848	fixation	_
23-17	3849-3855	string	_
23-18	3856-3857	(	_
23-19	3858-3859	“	_
23-20	3860-3864	XXXX	_
23-21	3865-3866	”	_
23-22	3867-3868	)	_
23-23	3869-3878	presented	_
23-24	3879-3882	for	_
23-25	3883-3887	1200	_
23-26	3888-3890	ms	_
23-27	3891-3892	.	_

24-1	3893-3905	Participants	_
24-2	3906-3910	were	_
24-3	3911-3921	instructed	_
24-4	3922-3924	to	_
24-5	3925-3932	respond	_
24-6	3933-3935	to	_
24-7	3936-3939	the	_
24-8	3940-3945	color	_
24-9	3946-3948	of	_
24-10	3949-3952	the	_
24-11	3953-3959	target	_
24-12	3960-3966	square	_
24-13	3967-3969	by	_
24-14	3970-3978	pressing	_
24-15	3979-3982	the	_
24-16	3983-3987	left	_
24-17	3988-3994	button	_
24-18	3995-3998	for	_
24-19	3999-4000	a	_
24-20	4001-4006	green	_
24-21	4007-4009	or	_
24-22	4010-4013	red	_
24-23	4014-4020	target	_
24-24	4021-4027	square	_
24-25	4028-4031	and	_
24-26	4032-4035	the	_
24-27	4036-4041	right	_
24-28	4042-4048	button	_
24-29	4049-4052	for	_
24-30	4053-4054	a	_
24-31	4055-4059	blue	_
24-32	4060-4062	or	_
24-33	4063-4069	yellow	_
24-34	4070-4076	target	_
24-35	4077-4083	square	_
24-36	4084-4085	,	_
24-37	4086-4091	using	_
24-38	4092-4097	their	_
24-39	4098-4103	index	_
24-40	4104-4111	fingers	_
24-41	4112-4113	.	_

25-1	4114-4116	On	_
25-2	4117-4126	congruent	_
25-3	4127-4128	(	_
25-4	4129-4131	CO	_
25-5	4132-4133	,	_
25-6	4134-4137	256	_
25-7	4138-4144	trials	_
25-8	4145-4146	,	_
25-9	4147-4149	50	_
25-10	4150-4151	%	_
25-11	4152-4153	)	_
25-12	4154-4155	,	_
25-13	4156-4159	the	_
25-14	4160-4167	targets	_
25-15	4168-4171	and	_
25-16	4172-4180	flankers	_
25-17	4181-4185	were	_
25-18	4186-4189	the	_
25-19	4190-4194	same	_
25-20	4195-4200	color	_
25-21	4201-4202	.	_

26-1	4203-4206	The	_
26-2	4207-4211	task	_
26-3	4212-4222	introduced	_
26-4	4223-4226	two	_
26-5	4227-4233	levels	_
26-6	4234-4236	of	_
26-7	4237-4245	conflict	_
26-8	4246-4250	when	_
26-9	4251-4254	the	_
26-10	4255-4261	target	_
26-11	4262-4265	and	_
26-12	4266-4273	flanker	_
26-13	4274-4278	were	_
26-14	4279-4288	displayed	_
26-15	4289-4291	in	_
26-16	4292-4301	different	_
26-17	4302-4308	colors	_
26-18	4309-4310	.	_

27-1	4311-4313	On	_
27-2	4314-4334	stimulus-incongruent	_
27-3	4335-4336	(	_
27-4	4337-4339	SI	_
27-5	4340-4341	,	_
27-6	4342-4345	128	_
27-7	4346-4352	trials	_
27-8	4353-4354	,	_
27-9	4355-4357	25	_
27-10	4358-4359	%	_
27-11	4360-4361	)	_
27-12	4362-4363	,	_
27-13	4364-4367	the	_
27-14	4368-4376	flankers	_
27-15	4377-4380	and	_
27-16	4381-4388	targets	_
27-17	4389-4397	differed	_
27-18	4398-4402	only	_
27-19	4403-4405	in	_
27-20	4406-4411	color	_
27-21	4412-4415	but	_
27-22	4416-4420	were	_
27-23	4421-4425	both	_
27-24	4426-4432	mapped	_
27-25	4433-4435	to	_
27-26	4436-4439	the	_
27-27	4440-4444	same	_
27-28	4445-4451	button	_
27-29	4452-4453	.	_

28-1	4454-4467	Alternatively	_
28-2	4468-4469	,	_
28-3	4470-4472	on	_
28-4	4473-4493	response-incongruent	_
28-5	4494-4495	(	_
28-6	4496-4498	RI	_
28-7	4499-4500	,	_
28-8	4501-4504	128	_
28-9	4505-4511	trials	_
28-10	4512-4513	,	_
28-11	4514-4516	25	_
28-12	4517-4518	%	_
28-13	4519-4520	)	_
28-14	4521-4522	,	_
28-15	4523-4526	the	_
28-16	4527-4534	flanker	_
28-17	4535-4538	and	_
28-18	4539-4545	target	_
28-19	4546-4552	colors	_
28-20	4553-4557	were	_
28-21	4558-4564	mapped	_
28-22	4565-4567	to	_
28-23	4568-4577	different	_
28-24	4578-4585	buttons	_
28-25	4586-4587	,	_
28-26	4588-4597	requiring	_
28-27	4598-4606	subjects	_
28-28	4607-4609	to	_
28-29	4610-4617	inhibit	_
28-30	4618-4631	inappropriate	_
28-31	4632-4641	responses	_
28-32	4642-4650	elicited	_
28-33	4651-4653	by	_
28-34	4654-4657	the	_
28-35	4658-4666	flankers	_
28-36	4667-4668	.	_

29-1	4669-4672	The	_
29-2	4673-4675	RI	_
29-3	4676-4679	and	_
29-4	4680-4682	SI	_
29-5	4683-4693	conditions	_
29-6	4694-4703	comprised	_
29-7	4704-4707	the	_
29-8	4708-4712	same	_
29-9	4713-4719	number	_
29-10	4720-4722	of	_
29-11	4723-4729	trials	_
29-12	4730-4731	,	_
29-13	4732-4735	and	_
29-14	4736-4739	the	_
29-15	4740-4745	color	_
29-16	4746-4758	distribution	_
29-17	4759-4762	was	_
29-18	4763-4778	counterbalanced	_
29-19	4779-4785	across	_
29-20	4786-4792	trials	_
29-21	4793-4794	.	_

30-1	4795-4802	Overall	_
30-2	4803-4804	,	_
30-3	4805-4809	half	_
30-4	4810-4812	of	_
30-5	4813-4816	the	_
30-6	4817-4823	trials	_
30-7	4824-4828	were	_
30-8	4829-4840	incongruous	_
30-9	4841-4844	but	_
30-10	4845-4848	the	_
30-11	4849-4857	response	_
30-12	4858-4864	switch	_
30-13	4865-4868	was	_
30-14	4869-4877	required	_
30-15	4878-4882	only	_
30-16	4883-4885	on	_
30-17	4886-4888	RI	_
30-18	4889-4895	trials	_
30-19	4896-4897	.	_

31-1	4898-4902	This	_
31-2	4903-4910	pattern	_
31-3	4911-4922	established	_
31-4	4923-4924	a	_
31-5	4925-4934	prepotent	_
31-6	4935-4943	response	_
31-7	4944-4949	which	_
31-8	4950-4952	is	_
31-9	4953-4961	commonly	_
31-10	4962-4966	used	_
31-11	4967-4969	in	_
31-12	4970-4975	tasks	_
31-13	4976-4983	probing	_
31-14	4984-4989	motor	_
31-15	4990-4997	control	_
31-16	4998-5002	such	_
31-17	5003-5005	as	_
31-18	5006-5007	a	_
31-19	5008-5015	go-nogo	_
31-20	5016-5020	task	_
31-21	5021-5022	.	_

32-1	5023-5024	A	_
32-2	5025-5030	total	_
32-3	5031-5033	of	_
32-4	5034-5037	512	_
32-5	5038-5044	trials	_
32-6	5045-5049	were	_
32-7	5050-5059	presented	_
32-8	5060-5065	every	_
32-9	5066-5070	1600	_
32-10	5071-5073	ms	_
32-11	5074-5079	using	_
32-12	5080-5092	Presentation	_
32-13	5093-5101	software	_
32-14	5102-5103	(	_
32-15	5104-5119	NeuroBehavioral	_
32-16	5120-5127	Systems	_
32-17	5128-5129	)	_
32-18	5130-5131	.	_

33-1	5132-5144	Participants	_
33-2	5145-5149	were	_
33-3	5150-5160	instructed	_
33-4	5161-5163	to	_
33-5	5164-5171	respond	_
33-6	5172-5174	as	_
33-7	5175-5182	quickly	_
33-8	5183-5185	as	_
33-9	5186-5194	possible	_
33-10	5195-5202	without	_
33-11	5203-5214	sacrificing	_
33-12	5215-5223	accuracy	_
33-13	5224-5225	.	_

34-1	5226-5238	Experimental	_
34-2	5239-5245	design	_
34-3	5246-5249	All	_
34-4	5250-5258	subjects	_
34-5	5259-5264	first	_
34-6	5265-5277	participated	_
34-7	5278-5280	in	_
34-8	5281-5283	an	_
34-9	5284-5296	introductory	_
34-10	5297-5304	session	_
34-11	5305-5311	during	_
34-12	5312-5317	which	_
34-13	5318-5322	they	_
34-14	5323-5327	were	_
34-15	5328-5340	familiarized	_
34-16	5341-5345	with	_
34-17	5346-5349	the	_
34-18	5350-5360	laboratory	_
34-19	5361-5368	setting	_
34-20	5369-5372	and	_
34-21	5373-5376	the	_
34-22	5377-5389	experimental	_
34-23	5390-5399	procedure	_
34-24	5400-5401	.	_

35-1	5402-5410	Subjects	_
35-2	5411-5423	subsequently	_
35-3	5424-5436	participated	_
35-4	5437-5439	in	_
35-5	5440-5444	both	_
35-6	5445-5452	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
35-7	5453-5456	and	_
35-8	5457-5464	placebo	_
35-9	5465-5468	MEG	_
35-10	5469-5477	sessions	_
35-11	5478-5480	in	_
35-12	5481-5482	a	_
35-13	5483-5498	counterbalanced	_
35-14	5499-5505	manner	_
35-15	5506-5507	.	_

36-1	5508-5511	The	_
36-2	5512-5526	within-subject	_
36-3	5527-5533	design	_
36-4	5534-5543	minimizes	_
36-5	5544-5553	influence	_
36-6	5554-5556	of	_
36-7	5557-5567	individual	_
36-8	5568-5579	differences	_
36-9	5580-5582	in	_
36-10	5583-5590	anatomy	_
36-11	5591-5592	,	_
36-12	5593-5600	alcohol	_
36-13	5601-5611	metabolism	_
36-14	5612-5613	,	_
36-15	5614-5617	and	_
36-16	5618-5623	brain	_
36-17	5624-5634	activation	_
36-18	5635-5643	patterns	_
36-19	5644-5645	,	_
36-20	5646-5655	resulting	_
36-21	5656-5658	in	_
36-22	5659-5666	reduced	_
36-23	5667-5672	error	_
36-24	5673-5681	variance	_
36-25	5682-5685	and	_
36-26	5686-5695	increased	_
36-27	5696-5707	statistical	_
36-28	5708-5713	power	_
36-29	5714-5715	.	_

37-1	5716-5723	Placebo	_
37-2	5724-5727	and	_
37-3	5728-5735	alcohol	_
37-4	5736-5744	sessions	_
37-5	5745-5749	were	_
37-6	5750-5752	33	_
37-7	5753-5754	±	_
37-8	5755-5757	28	_
37-9	5758-5762	days	_
37-10	5763-5768	apart	_
37-11	5769-5771	on	_
37-12	5772-5779	average	_
37-13	5780-5781	.	_

38-1	5782-5787	Urine	_
38-2	5788-5797	pregnancy	_
38-3	5798-5803	tests	_
38-4	5804-5816	administered	_
38-5	5817-5819	to	_
38-6	5820-5825	women	_
38-7	5826-5828	in	_
38-8	5829-5832	the	_
38-9	5833-5842	beginning	_
38-10	5843-5845	of	_
38-11	5846-5850	each	_
38-12	5851-5858	session	_
38-13	5859-5870	ascertained	_
38-14	5871-5875	that	_
38-15	5876-5880	none	_
38-16	5881-5884	was	_
38-17	5885-5893	pregnant	_
38-18	5894-5895	.	_

39-1	5896-5899	All	_
39-2	5900-5908	subjects	_
39-3	5909-5913	were	_
39-4	5914-5919	asked	_
39-5	5920-5922	to	_
39-6	5923-5930	abstain	_
39-7	5931-5935	from	_
39-8	5936-5940	food	_
39-9	5941-5944	for	_
39-10	5945-5946	3	_
39-11	5947-5952	hours	_
39-12	5953-5956	and	_
39-13	5957-5961	from	_
39-14	5962-5969	alcohol	_
39-15	5970-5972	at	_
39-16	5973-5978	least	_
39-17	5979-5981	48	_
39-18	5982-5987	hours	_
39-19	5988-5993	prior	_
39-20	5994-5996	to	_
39-21	5997-6001	each	_
39-22	6002-6014	experimental	_
39-23	6015-6022	session	_
39-24	6023-6024	.	_

40-1	6025-6031	Breath	_
40-2	6032-6039	alcohol	_
40-3	6040-6053	concentration	_
40-4	6054-6055	(	_
40-5	6056-6060	BrAC	_
40-6	6061-6062	)	_
40-7	6063-6066	was	_
40-8	6067-6075	measured	_
40-9	6076-6080	with	_
40-10	6081-6082	a	_
40-11	6083-6095	breathalyzer	_
40-12	6096-6097	(	_
40-13	6098-6105	Draeger	_
40-14	6106-6107	,	_
40-15	6108-6112	Inc.	_
40-16	6113-6114	)	_
40-17	6115-6125	throughout	_
40-18	6126-6129	the	_
40-19	6130-6139	recording	_
40-20	6140-6147	session	_
40-21	6148-6149	.	_

41-1	6150-6153	The	_
41-2	6154-6162	subjects	_
41-3	6163-6168	rated	_
41-4	6169-6174	their	_
41-5	6175-6180	moods	_
41-6	6181-6184	and	_
41-7	6185-6193	feelings	_
41-8	6194-6198	with	_
41-9	6199-6202	the	_
41-10	6203-6211	Biphasic	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-11	6212-6219	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-12	6220-6227	Effects	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-13	6228-6233	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-14	6234-6235	(	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-15	6236-6240	BAES	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-16	6241-6242	)	http://maven.renci.org/NeuroBridge/neurobridge#BiphasicAlcoholEffectsScale
41-17	6243-6248	prior	_
41-18	6249-6251	to	_
41-19	6252-6260	drinking	_
41-20	6261-6262	(	_
41-21	6263-6265	at	_
41-22	6266-6274	baseline	_
41-23	6275-6276	)	_
41-24	6277-6280	and	_
41-25	6281-6283	on	_
41-26	6284-6287	the	_
41-27	6288-6297	ascending	_
41-28	6298-6301	and	_
41-29	6302-6312	descending	_
41-30	6313-6317	BrAC	_
41-31	6318-6323	limbs	_
41-32	6324-6325	.	_

42-1	6326-6328	In	_
42-2	6329-6333	each	_
42-3	6334-6346	experimental	_
42-4	6347-6354	session	_
42-5	6355-6356	,	_
42-6	6357-6363	either	_
42-7	6364-6371	alcohol	_
42-8	6372-6373	(	_
42-9	6374-6378	0.60	_
42-10	6379-6383	g/kg	_
42-11	6384-6387	for	_
42-12	6388-6391	men	_
42-13	6392-6393	,	_
42-14	6394-6398	0.55	_
42-15	6399-6403	g/kg	_
42-16	6404-6407	for	_
42-17	6408-6413	women	_
42-18	6414-6415	,	_
42-19	6416-6418	in	_
42-20	6419-6420	a	_
42-21	6421-6429	cocktail	_
42-22	6430-6440	containing	_
42-23	6441-6446	vodka	_
42-24	6447-6448	(	_
42-25	6449-6453	Grey	_
42-26	6454-6459	Goose	_
42-27	6460-6461	,	_
42-28	6462-6469	Bacardi	_
42-29	6470-6471	)	_
42-30	6472-6474	as	_
42-31	6475-6477	20	_
42-32	6478-6479	%	_
42-33	6480-6483	v/v	_
42-34	6484-6486	in	_
42-35	6487-6493	orange	_
42-36	6494-6499	juice	_
42-37	6500-6501	)	_
42-38	6502-6503	,	_
42-39	6504-6506	or	_
42-40	6507-6514	placebo	_
42-41	6515-6516	(	_
42-42	6517-6520	the	_
42-43	6521-6525	same	_
42-44	6526-6532	volume	_
42-45	6533-6535	of	_
42-46	6536-6542	orange	_
42-47	6543-6548	juice	_
42-48	6549-6550	)	_
42-49	6551-6555	were	_
42-50	6556-6568	administered	_
42-51	6569-6571	to	_
42-52	6572-6575	the	_
42-53	6576-6588	participants	_
42-54	6589-6590	.	_

43-1	6591-6594	The	_
43-2	6595-6599	task	_
43-3	6600-6603	was	_
43-4	6604-6616	administered	_
43-5	6617-6622	close	_
43-6	6623-6625	to	_
43-7	6626-6629	the	_
43-8	6630-6634	peak	_
43-9	6635-6637	on	_
43-10	6638-6641	the	_
43-11	6642-6652	descending	_
43-12	6653-6657	limb	_
43-13	6658-6660	of	_
43-14	6661-6664	the	_
43-15	6665-6669	BrAC	_
43-16	6670-6671	,	_
43-17	6672-6674	as	_
43-18	6675-6678	the	_
43-19	6679-6686	average	_
43-20	6687-6691	BrAC	_
43-21	6692-6698	levels	_
43-22	6699-6703	were	_
43-23	6704-6709	0.058	_
43-24	6710-6711	±	_
43-25	6712-6717	0.012	_
43-26	6718-6724	before	_
43-27	6725-6728	and	_
43-28	6729-6734	0.051	_
43-29	6735-6736	±	_
43-30	6737-6742	0.010	_
43-31	6743-6748	after	_
43-32	6749-6752	the	_
43-33	6753-6757	task	_
43-34	6758-6759	.	_

44-1	6760-6764	Upon	_
44-2	6765-6775	completion	_
44-3	6776-6778	of	_
44-4	6779-6783	each	_
44-5	6784-6791	session	_
44-6	6792-6795	the	_
44-7	6796-6808	participants	_
44-8	6809-6814	rated	_
44-9	6815-6819	task	_
44-10	6820-6830	difficulty	_
44-11	6831-6832	,	_
44-12	6833-6842	estimated	_
44-13	6843-6846	the	_
44-14	6847-6855	quantity	_
44-15	6856-6858	of	_
44-16	6859-6866	alcohol	_
44-17	6867-6871	they	_
44-18	6872-6877	drank	_
44-19	6878-6879	,	_
44-20	6880-6883	and	_
44-21	6884-6892	reported	_
44-22	6893-6896	how	_
44-23	6897-6908	intoxicated	_
44-24	6909-6911	or	_
44-25	6912-6920	nauseous	_
44-26	6921-6925	they	_
44-27	6926-6930	felt	_
44-28	6931-6932	.	_

45-1	6933-6947	Transportation	_
45-2	6948-6952	home	_
45-3	6953-6956	was	_
45-4	6957-6965	provided	_
45-5	6966-6968	to	_
45-6	6969-6972	all	_
45-7	6973-6985	participants	_
45-8	6986-6987	.	_

46-1	6988-7003	High-resolution	_
46-2	7004-7014	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
46-3	7015-7018	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
46-4	7019-7024	scans	_
46-5	7025-7029	were	_
46-6	7030-7038	obtained	_
46-7	7039-7043	from	_
46-8	7044-7047	all	_
46-9	7048-7060	participants	_
46-10	7061-7063	in	_
46-11	7064-7065	a	_
46-12	7066-7074	separate	_
46-13	7075-7082	session	_
46-14	7083-7084	.	_

47-1	7085-7089	Data	_
47-2	7090-7101	acquisition	_
47-3	7102-7105	and	_
47-4	7106-7114	analyses	_
47-5	7115-7118	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
47-6	7119-7129	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
47-7	7130-7133	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
47-8	7134-7140	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
47-9	7141-7145	were	_
47-10	7146-7154	acquired	_
47-11	7155-7157	on	_
47-12	7158-7159	a	_
47-13	7160-7162	3T	_
47-14	7163-7170	Siemens	_
47-15	7171-7175	Trio	_
47-16	7176-7186	whole-body	_
47-17	7187-7194	scanner	_
47-18	7195-7196	(	_
47-19	7197-7204	Siemens	_
47-20	7205-7206	,	_
47-21	7207-7215	Erlangen	_
47-22	7216-7217	)	_
47-23	7218-7219	.	_

48-1	7220-7223	Two	_
48-2	7224-7239	high-resolution	_
48-3	7240-7242	3D	http://maven.renci.org/NeuroBridge/neurobridge#Age
48-4	7243-7250	MP-RAGE	http://maven.renci.org/NeuroBridge/neurobridge#Age
48-5	7251-7262	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-6	7263-7272	sequences	_
48-7	7273-7277	were	_
48-8	7278-7286	obtained	_
48-9	7287-7290	for	_
48-10	7291-7295	each	_
48-11	7296-7303	subject	_
48-12	7304-7305	(	_
48-13	7306-7308	TR	_
48-14	7309-7310	=	_
48-15	7311-7315	2.53	_
48-16	7316-7319	sec	_
48-17	7320-7321	,	_
48-18	7322-7324	TE	_
48-19	7325-7326	=	_
48-20	7327-7331	3.25	_
48-21	7332-7334	ms	_
48-22	7335-7336	,	_
48-23	7337-7341	flip	_
48-24	7342-7347	angle	_
48-25	7348-7349	=	_
48-26	7350-7351	7	_
48-27	7352-7359	degrees	_
48-28	7360-7361	,	_
48-29	7362-7365	FOV	_
48-30	7366-7367	=	_
48-31	7368-7371	256	_
48-32	7372-7373	,	_
48-33	7374-7377	128	_
48-34	7378-7386	sagittal	_
48-35	7387-7393	slices	_
48-36	7394-7395	,	_
48-37	7396-7400	1.33	_
48-38	7401-7403	mm	_
48-39	7404-7413	thickness	_
48-40	7414-7415	,	_
48-41	7416-7424	in-plane	_
48-42	7425-7435	resolution	_
48-43	7436-7437	1	_
48-44	7438-7439	x	_
48-45	7440-7441	1	_
48-46	7442-7444	mm	_
48-47	7445-7446	)	_
48-48	7447-7450	and	_
48-49	7451-7455	used	_
48-50	7456-7458	to	_
48-51	7459-7470	reconstruct	_
48-52	7471-7475	each	_
48-53	7476-7482	person	_
48-54	7483-7485	's	_
48-55	7486-7494	cortical	_
48-56	7495-7502	surface	_
48-57	7503-7504	.	_

49-1	7505-7508	The	_
49-2	7509-7514	inner	_
49-3	7515-7520	skull	_
49-4	7521-7528	surface	_
49-5	7529-7536	derived	_
49-6	7537-7541	from	_
49-7	7542-7545	the	_
49-8	7546-7555	segmented	_
49-9	7556-7559	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
49-10	7560-7564	data	_
49-11	7565-7568	was	_
49-12	7569-7573	used	_
49-13	7574-7577	for	_
49-14	7578-7579	a	_
49-15	7580-7588	boundary	_
49-16	7589-7596	element	_
49-17	7597-7602	model	_
49-18	7603-7605	of	_
49-19	7606-7609	the	_
49-20	7610-7616	volume	_
49-21	7617-7626	conductor	_
49-22	7627-7629	in	_
49-23	7630-7633	the	_
49-24	7634-7641	forward	_
49-25	7642-7654	calculations	_
49-26	7655-7656	.	_

50-1	7657-7660	The	_
50-2	7661-7669	solution	_
50-3	7670-7675	space	_
50-4	7676-7679	was	_
50-5	7680-7692	approximated	_
50-6	7693-7695	by	_
50-7	7696-7701	~5000	_
50-8	7702-7715	free-rotating	_
50-9	7716-7723	dipoles	_
50-10	7724-7729	along	_
50-11	7730-7733	the	_
50-12	7734-7744	gray-white	_
50-13	7745-7751	matter	_
50-14	7752-7759	surface	_
50-15	7760-7762	in	_
50-16	7763-7766	the	_
50-17	7767-7773	cortex	_
50-18	7774-7775	,	_
50-19	7776-7780	with	_
50-20	7781-7788	spacing	_
50-21	7789-7796	between	_
50-22	7797-7803	dipole	_
50-23	7804-7813	locations	_
50-24	7814-7816	~7	_
50-25	7817-7819	mm	_
50-26	7820-7821	.	_

51-1	7822-7825	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
51-2	7826-7838	High-density	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
51-3	7839-7842	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography
51-4	7843-7850	signals	_
51-5	7851-7855	were	_
51-6	7856-7864	recorded	_
51-7	7865-7869	with	_
51-8	7870-7871	a	_
51-9	7872-7882	whole-head	_
51-10	7883-7891	Neuromag	_
51-11	7892-7902	Vectorview	_
51-12	7903-7909	system	_
51-13	7910-7911	(	_
51-14	7912-7918	Elekta	_
51-15	7919-7920	)	_
51-16	7921-7923	in	_
51-17	7924-7925	a	_
51-18	7926-7938	magnetically	_
51-19	7939-7942	and	_
51-20	7943-7955	electrically	_
51-21	7956-7964	shielded	_
51-22	7965-7969	room	_
51-23	7970-7971	.	_

52-1	7972-7975	The	_
52-2	7976-7983	signals	_
52-3	7984-7988	were	_
52-4	7989-7997	recorded	_
52-5	7998-8010	continuously	_
52-6	8011-8015	with	_
52-7	8016-8019	601	_
52-8	8020-8022	Hz	_
52-9	8023-8031	sampling	_
52-10	8032-8036	rate	_
52-11	8037-8040	and	_
52-12	8041-8048	minimal	_
52-13	8049-8058	filtering	_
52-14	8059-8060	(	_
52-15	8061-8064	0.1	_
52-16	8065-8067	to	_
52-17	8068-8071	200	_
52-18	8072-8074	Hz	_
52-19	8075-8076	)	_
52-20	8077-8078	.	_

53-1	8079-8082	The	_
53-2	8083-8091	location	_
53-3	8092-8094	of	_
53-4	8095-8099	head	_
53-5	8100-8108	position	_
53-6	8109-8118	indicator	_
53-7	8119-8120	(	_
53-8	8121-8124	HPI	_
53-9	8125-8126	)	_
53-10	8127-8132	coils	_
53-11	8133-8134	,	_
53-12	8135-8138	the	_
53-13	8139-8143	main	_
53-14	8144-8153	fiduciary	_
53-15	8154-8160	points	_
53-16	8161-8162	(	_
53-17	8163-8167	i.e.	_
53-18	8168-8169	,	_
53-19	8170-8173	the	_
53-20	8174-8180	nasion	_
53-21	8181-8184	and	_
53-22	8185-8197	preauricular	_
53-23	8198-8204	points	_
53-24	8205-8206	)	_
53-25	8207-8210	and	_
53-26	8211-8212	a	_
53-27	8213-8218	large	_
53-28	8219-8224	array	_
53-29	8225-8227	of	_
53-30	8228-8234	random	_
53-31	8235-8241	points	_
53-32	8242-8250	covering	_
53-33	8251-8254	the	_
53-34	8255-8260	scalp	_
53-35	8261-8265	were	_
53-36	8266-8275	digitized	_
53-37	8276-8280	with	_
53-38	8281-8287	3Space	_
53-39	8288-8295	Isotrak	_
53-40	8296-8298	II	_
53-41	8299-8300	(	_
53-42	8301-8309	Polhemus	_
53-43	8310-8311	)	_
53-44	8312-8318	system	_
53-45	8319-8322	for	_
53-46	8323-8333	subsequent	_
53-47	8334-8341	precise	_
53-48	8342-8357	co-registration	_
53-49	8358-8362	with	_
53-50	8363-8373	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
53-51	8374-8377	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
53-52	8378-8384	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
53-53	8385-8386	.	_

54-1	8387-8390	MEG	_
54-2	8391-8395	data	_
54-3	8396-8404	analysis	_
54-4	8405-8411	stream	_
54-5	8412-8415	has	_
54-6	8416-8420	been	_
54-7	8421-8430	described	_
54-8	8431-8433	in	_
54-9	8434-8442	previous	_
54-10	8443-8455	publications	_
54-11	8456-8457	.	_

55-1	8458-8460	It	_
55-2	8461-8470	primarily	_
55-3	8471-8475	uses	_
55-4	8476-8482	custom	_
55-5	8483-8489	MATLAB	_
55-6	8490-8499	functions	_
55-7	8500-8503	and	_
55-8	8504-8510	relies	_
55-9	8511-8517	partly	_
55-10	8518-8520	on	_
55-11	8521-8529	publicly	_
55-12	8530-8539	available	_
55-13	8540-8548	packages	_
55-14	8549-8558	including	_
55-15	8559-8568	FieldTrip	_
55-16	8569-8570	,	_
55-17	8571-8577	EEGLab	_
55-18	8578-8579	,	_
55-19	8580-8583	and	_
55-20	8584-8587	MNE	_
55-21	8588-8589	.	_

56-1	8590-8594	Data	_
56-2	8595-8599	from	_
56-3	8600-8603	204	_
56-4	8604-8612	channels	_
56-5	8613-8614	(	_
56-6	8615-8618	102	_
56-7	8619-8624	pairs	_
56-8	8625-8627	of	_
56-9	8628-8634	planar	_
56-10	8635-8647	gradiometers	_
56-11	8648-8649	)	_
56-12	8650-8654	were	_
56-13	8655-8663	analyzed	_
56-14	8664-8666	in	_
56-15	8667-8671	beta	_
56-16	8672-8673	(	_
56-17	8674-8679	15–25	_
56-18	8680-8682	Hz	_
56-19	8683-8684	)	_
56-20	8685-8688	and	_
56-21	8689-8694	theta	_
56-22	8695-8696	(	_
56-23	8697-8700	4–7	_
56-24	8701-8703	Hz	_
56-25	8704-8705	)	_
56-26	8706-8715	frequency	_
56-27	8716-8721	bands	_
56-28	8722-8723	.	_

57-1	8724-8728	Data	_
57-2	8729-8733	from	_
57-3	8734-8737	the	_
57-4	8738-8748	additional	_
57-5	8749-8752	102	_
57-6	8753-8766	magnetometers	_
57-7	8767-8771	were	_
57-8	8772-8775	not	_
57-9	8776-8784	included	_
57-10	8785-8787	in	_
57-11	8788-8791	the	_
57-12	8792-8800	analysis	_
57-13	8801-8802	.	_

58-1	8803-8808	After	_
58-2	8809-8818	wide-band	_
58-3	8819-8828	filtering	_
58-4	8829-8830	(	_
58-5	8831-8834	0.1	_
58-6	8835-8837	to	_
58-7	8838-8841	100	_
58-8	8842-8844	Hz	_
58-9	8845-8846	)	_
58-10	8847-8848	,	_
58-11	8849-8853	data	_
58-12	8854-8858	were	_
58-13	8859-8866	epoched	_
58-14	8867-8871	from	_
58-15	8872-8876	-400	_
58-16	8877-8879	to	_
58-17	8880-8883	600	_
58-18	8884-8886	ms	_
58-19	8887-8895	relative	_
58-20	8896-8898	to	_
58-21	8899-8903	each	_
58-22	8904-8910	target	_
58-23	8911-8916	onset	_
58-24	8917-8920	for	_
58-25	8921-8924	the	_
58-26	8925-8940	stimulus-locked	_
58-27	8941-8949	analysis	_
58-28	8950-8953	and	_
58-29	8954-8957	300	_
58-30	8958-8960	ms	_
58-31	8961-8967	before	_
58-32	8968-8971	and	_
58-33	8972-8977	after	_
58-34	8978-8986	response	_
58-35	8987-8988	(	_
58-36	8989-8993	i.e.	_
58-37	8994-8995	,	_
58-38	8996-9002	button	_
58-39	9003-9008	press	_
58-40	9009-9010	)	_
58-41	9011-9014	for	_
58-42	9015-9018	the	_
58-43	9019-9034	response-locked	_
58-44	9035-9043	analysis	_
58-45	9044-9045	.	_

59-1	9046-9049	For	_
59-2	9050-9053	the	_
59-3	9054-9058	beta	_
59-4	9059-9063	band	_
59-5	9064-9065	,	_
59-6	9066-9074	analysis	_
59-7	9075-9078	was	_
59-8	9079-9086	carried	_
59-9	9087-9090	out	_
59-10	9091-9101	separately	_
59-11	9102-9105	for	_
59-12	9106-9110	each	_
59-13	9111-9121	responding	_
59-14	9122-9126	hand	_
59-15	9127-9129	to	_
59-16	9130-9137	examine	_
59-17	9138-9148	laterality	_
59-18	9149-9151	of	_
59-19	9152-9155	the	_
59-20	9156-9171	spatio-temporal	_
59-21	9172-9178	stages	_
59-22	9179-9181	of	_
59-23	9182-9187	motor	_
59-24	9188-9199	preparation	_
59-25	9200-9203	and	_
59-26	9204-9213	execution	_
59-27	9214-9216	in	_
59-28	9217-9224	greater	_
59-29	9225-9231	detail	_
59-30	9232-9233	.	_

60-1	9234-9245	Independent	_
60-2	9246-9255	component	_
60-3	9256-9264	analysis	_
60-4	9265-9268	was	_
60-5	9269-9273	used	_
60-6	9274-9276	to	_
60-7	9277-9283	remove	_
60-8	9284-9293	heartbeat	_
60-9	9294-9297	and	_
60-10	9298-9306	eyeblink	_
60-11	9307-9316	artifacts	_
60-12	9317-9318	.	_

61-1	9319-9322	Any	_
61-2	9323-9332	remaining	_
61-3	9333-9342	artifacts	_
61-4	9343-9347	were	_
61-5	9348-9355	removed	_
61-6	9356-9360	with	_
61-7	9361-9370	threshold	_
61-8	9371-9380	rejection	_
61-9	9381-9384	and	_
61-10	9385-9392	careful	_
61-11	9393-9399	visual	_
61-12	9400-9410	inspection	_
61-13	9411-9412	.	_

62-1	9413-9421	Baseline	_
62-2	9422-9432	correction	_
62-3	9433-9436	was	_
62-4	9437-9446	performed	_
62-5	9447-9449	on	_
62-6	9450-9454	each	_
62-7	9455-9460	epoch	_
62-8	9461-9463	by	_
62-9	9464-9473	averaging	_
62-10	9474-9478	over	_
62-11	9479-9480	a	_
62-12	9481-9486	200ms	_
62-13	9487-9495	baseline	_
62-14	9496-9505	preceding	_
62-15	9506-9509	the	_
62-16	9510-9517	flanker	_
62-17	9518-9530	presentation	_
62-18	9531-9534	and	_
62-19	9535-9546	subtracting	_
62-20	9547-9551	this	_
62-21	9552-9559	average	_
62-22	9560-9564	from	_
62-23	9565-9569	each	_
62-24	9570-9576	sample	_
62-25	9577-9579	in	_
62-26	9580-9583	the	_
62-27	9584-9589	epoch	_
62-28	9590-9591	.	_

63-1	9592-9596	Only	_
63-2	9597-9610	artifact-free	_
63-3	9611-9617	trials	_
63-4	9618-9622	with	_
63-5	9623-9630	correct	_
63-6	9631-9640	responses	_
63-7	9641-9645	were	_
63-8	9646-9654	included	_
63-9	9655-9657	in	_
63-10	9658-9661	the	_
63-11	9662-9670	analysis	_
63-12	9671-9672	.	_

64-1	9673-9675	To	_
64-2	9676-9685	eliminate	_
64-3	9686-9695	potential	_
64-4	9696-9700	bias	_
64-5	9701-9704	due	_
64-6	9705-9707	to	_
64-7	9708-9715	unequal	_
64-8	9716-9722	number	_
64-9	9723-9725	of	_
64-10	9726-9732	trials	_
64-11	9733-9734	,	_
64-12	9735-9741	trials	_
64-13	9742-9746	were	_
64-14	9747-9754	equated	_
64-15	9755-9761	across	_
64-16	9762-9770	beverage	_
64-17	9771-9774	and	_
64-18	9775-9779	task	_
64-19	9780-9790	conditions	_
64-20	9791-9794	for	_
64-21	9795-9799	each	_
64-22	9800-9807	subject	_
64-23	9808-9810	by	_
64-24	9811-9820	excluding	_
64-25	9821-9829	randomly	_
64-26	9830-9838	selected	_
64-27	9839-9850	superfluous	_
64-28	9851-9857	trials	_
64-29	9858-9862	with	_
64-30	9863-9865	an	_
64-31	9866-9873	average	_
64-32	9874-9876	of	_
64-33	9877-9879	85	_
64-34	9880-9883	+/-	_
64-35	9884-9886	15	_
64-36	9887-9893	trials	_
64-37	9894-9903	remaining	_
64-38	9904-9907	for	_
64-39	9908-9912	each	_
64-40	9913-9922	condition	_
64-41	9923-9924	.	_

65-1	9925-9932	Complex	_
65-2	9933-9938	power	_
65-3	9939-9946	spectra	_
65-4	9947-9951	were	_
65-5	9952-9962	calculated	_
65-6	9963-9966	for	_
65-7	9967-9971	each	_
65-8	9972-9977	trial	_
65-9	9978-9982	with	_
65-10	9983-9989	Morlet	_
65-11	9990-9998	wavelets	_
65-12	9999-10001	in	_
65-13	10002-10003	2	_
65-14	10004-10006	Hz	_
65-15	10007-10017	increments	_
65-16	10018-10021	for	_
65-17	10022-10026	beta	_
65-18	10027-10030	and	_
65-19	10031-10032	1	_
65-20	10033-10035	Hz	_
65-21	10036-10046	increments	_
65-22	10047-10050	for	_
65-23	10051-10056	theta	_
65-24	10057-10058	.	_

66-1	10059-10066	Padding	_
66-2	10067-10070	was	_
66-3	10071-10076	added	_
66-4	10077-10079	to	_
66-5	10080-10084	each	_
66-6	10085-10090	epoch	_
66-7	10091-10094	and	_
66-8	10095-10099	then	_
66-9	10100-10109	discarded	_
66-10	10110-10112	to	_
66-11	10113-10119	remove	_
66-12	10120-10124	edge	_
66-13	10125-10134	artifacts	_
66-14	10135-10139	from	_
66-15	10140-10147	wavelet	_
66-16	10148-10156	analysis	_
66-17	10157-10158	.	_

67-1	10159-10164	Power	_
67-2	10165-10170	plots	_
67-3	10171-10174	for	_
67-4	10175-10178	all	_
67-5	10179-10185	trials	_
67-6	10186-10190	were	_
67-7	10191-10200	inspected	_
67-8	10201-10204	for	_
67-9	10205-10213	possible	_
67-10	10214-10223	remaining	_
67-11	10224-10233	artifacts	_
67-12	10234-10235	.	_

68-1	10236-10241	Empty	_
68-2	10242-10246	room	_
68-3	10247-10251	data	_
68-4	10252-10258	pooled	_
68-5	10259-10265	across	_
68-6	10266-10274	sessions	_
68-7	10275-10279	were	_
68-8	10280-10284	used	_
68-9	10285-10287	to	_
68-10	10288-10296	estimate	_
68-11	10297-10300	the	_
68-12	10301-10306	noise	_
68-13	10307-10317	covariance	_
68-14	10318-10321	for	_
68-15	10322-10325	the	_
68-16	10326-10337	calculation	_
68-17	10338-10340	of	_
68-18	10341-10344	the	_
68-19	10345-10352	inverse	_
68-20	10353-10361	operator	_
68-21	10362-10365	and	_
68-22	10366-10368	to	_
68-23	10369-10376	prevent	_
68-24	10377-10384	biasing	_
68-25	10385-10388	the	_
68-26	10389-10396	inverse	_
68-27	10397-10405	solution	_
68-28	10406-10413	against	_
68-29	10414-10425	spontaneous	_
68-30	10426-10431	brain	_
68-31	10432-10444	oscillations	_
68-32	10445-10446	.	_

69-1	10447-10452	Empty	_
69-2	10453-10457	room	_
69-3	10458-10462	data	_
69-4	10463-10467	were	_
69-5	10468-10477	band-pass	_
69-6	10478-10486	filtered	_
69-7	10487-10494	between	_
69-8	10495-10496	3	_
69-9	10497-10500	and	_
69-10	10501-10503	50	_
69-11	10504-10506	Hz	_
69-12	10507-10508	.	_

70-1	10509-10512	The	_
70-2	10513-10518	noise	_
70-3	10519-10529	covariance	_
70-4	10530-10536	matrix	_
70-5	10537-10540	was	_
70-6	10541-10547	scaled	_
70-7	10548-10550	by	_
70-8	10551-10554	the	_
70-9	10555-10569	regularization	_
70-10	10570-10579	parameter	_
70-11	10580-10581	,	_
70-12	10582-10595	incorporating	_
70-13	10596-10599	the	_
70-14	10600-10608	estimate	_
70-15	10609-10611	of	_
70-16	10612-10627	signal-to-noise	_
70-17	10628-10633	ratio	_
70-18	10634-10635	(	_
70-19	10636-10639	SNR	_
70-20	10640-10641	)	_
70-21	10642-10650	equaling	_
70-22	10651-10652	5	_
70-23	10653-10654	.	_

71-1	10655-10663	Identity	_
71-2	10664-10670	matrix	_
71-3	10671-10674	was	_
71-4	10675-10679	used	_
71-5	10680-10683	for	_
71-6	10684-10701	noise-sensitivity	_
71-7	10702-10715	normalization	_
71-8	10716-10718	of	_
71-9	10719-10722	the	_
71-10	10723-10735	source-space	_
71-11	10736-10744	solution	_
71-12	10745-10746	.	_

72-1	10747-10753	Source	_
72-2	10754-10759	power	_
72-3	10760-10769	estimates	_
72-4	10770-10774	were	_
72-5	10775-10783	obtained	_
72-6	10784-10788	with	_
72-7	10789-10790	a	_
72-8	10791-10808	noise-sensitivity	_
72-9	10809-10819	normalized	_
72-10	10820-10832	anatomically	_
72-11	10833-10844	constrained	_
72-12	10845-10852	minimum	_
72-13	10853-10857	norm	_
72-14	10858-10863	model	_
72-15	10864-10867	for	_
72-16	10868-10872	both	_
72-17	10873-10876	the	_
72-18	10877-10881	beta	_
72-19	10882-10885	and	_
72-20	10886-10891	theta	_
72-21	10892-10897	bands	_
72-22	10898-10899	.	_

73-1	10900-10903	The	_
73-2	10904-10913	estimates	_
73-3	10914-10916	of	_
73-4	10917-10923	source	_
73-5	10924-10929	power	_
73-6	10930-10933	and	_
73-7	10934-10939	phase	_
73-8	10940-10944	were	_
73-9	10945-10953	obtained	_
73-10	10954-10956	at	_
73-11	10957-10961	each	_
73-12	10962-10970	location	_
73-13	10971-10973	on	_
73-14	10974-10977	the	_
73-15	10978-10986	cortical	_
73-16	10987-10994	surface	_
73-17	10995-10998	for	_
73-18	10999-11003	each	_
73-19	11004-11009	trial	_
73-20	11010-11013	and	_
73-21	11014-11016	at	_
73-22	11017-11021	each	_
73-23	11022-11031	frequency	_
73-24	11032-11033	,	_
73-25	11034-11037	and	_
73-26	11038-11042	then	_
73-27	11043-11051	averaged	_
73-28	11052-11058	across	_
73-29	11059-11063	band	_
73-30	11064-11075	frequencies	_
73-31	11076-11077	(	_
73-32	11078-11082	beta	_
73-33	11083-11084	:	_
73-34	11085-11090	15–25	_
73-35	11091-11093	Hz	_
73-36	11094-11095	;	_
73-37	11096-11101	theta	_
73-38	11102-11103	:	_
73-39	11104-11107	4–7	_
73-40	11108-11110	Hz	_
73-41	11111-11112	)	_
73-42	11113-11116	and	_
73-43	11117-11123	across	_
73-44	11124-11130	trials	_
73-45	11131-11134	for	_
73-46	11135-11139	each	_
73-47	11140-11149	condition	_
73-48	11150-11151	.	_

74-1	11152-11159	Finally	_
74-2	11160-11161	,	_
74-3	11162-11175	event-related	_
74-4	11176-11181	power	_
74-5	11182-11191	estimates	_
74-6	11192-11196	were	_
74-7	11197-11206	expressed	_
74-8	11207-11209	as	_
74-9	11210-11217	percent	_
74-10	11218-11224	signal	_
74-11	11225-11231	change	_
74-12	11232-11236	from	_
74-13	11237-11245	baseline	_
74-14	11246-11256	calculated	_
74-15	11257-11260	for	_
74-16	11261-11264	the	_
74-17	11265-11268	200	_
74-18	11269-11271	ms	_
74-19	11272-11278	period	_
74-20	11279-11288	preceding	_
74-21	11289-11292	the	_
74-22	11293-11300	flanker	_
74-23	11301-11302	.	_

75-1	11303-11308	Group	_
75-2	11309-11317	averages	_
75-3	11318-11322	were	_
75-4	11323-11330	created	_
75-5	11331-11333	by	_
75-6	11334-11342	morphing	_
75-7	11343-11347	each	_
75-8	11348-11355	subject	_
75-9	11356-11357	’	_
75-10	11358-11359	s	_
75-11	11360-11373	reconstructed	_
75-12	11374-11381	surface	_
75-13	11382-11386	into	_
75-14	11387-11389	an	_
75-15	11390-11397	average	_
75-16	11398-11412	representation	_
75-17	11413-11415	by	_
75-18	11416-11424	aligning	_
75-19	11425-11430	their	_
75-20	11431-11439	cortical	_
75-21	11440-11452	sulcal-gyral	_
75-22	11453-11461	patterns	_
75-23	11462-11465	and	_
75-24	11466-11475	averaging	_
75-25	11476-11486	individual	_
75-26	11487-11493	source	_
75-27	11494-11499	power	_
75-28	11500-11509	estimates	_
75-29	11510-11511	.	_

76-1	11512-11518	Region	_
76-2	11519-11521	of	_
76-3	11522-11530	interest	_
76-4	11531-11532	(	_
76-5	11533-11536	ROI	_
76-6	11537-11538	)	_
76-7	11539-11547	analysis	_
76-8	11548-11551	was	_
76-9	11552-11561	conducted	_
76-10	11562-11564	to	_
76-11	11565-11572	examine	_
76-12	11573-11581	possible	_
76-13	11582-11594	interactions	_
76-14	11595-11597	of	_
76-15	11598-11601	the	_
76-16	11602-11609	factors	_
76-17	11610-11612	of	_
76-18	11613-11617	task	_
76-19	11618-11627	condition	_
76-20	11628-11631	and	_
76-21	11632-11640	beverage	_
76-22	11641-11643	on	_
76-23	11644-11651	changes	_
76-24	11652-11654	in	_
76-25	11655-11659	beta	_
76-26	11660-11663	and	_
76-27	11664-11669	theta	_
76-28	11670-11675	power	_
76-29	11676-11677	.	_

77-1	11678-11682	ROIs	_
77-2	11683-11687	were	_
77-3	11688-11695	created	_
77-4	11696-11701	based	_
77-5	11702-11704	on	_
77-6	11705-11712	overall	_
77-7	11713-11719	source	_
77-8	11720-11725	power	_
77-9	11726-11734	averages	_
77-10	11735-11741	across	_
77-11	11742-11745	all	_
77-12	11746-11754	subjects	_
77-13	11755-11756	,	_
77-14	11757-11761	task	_
77-15	11762-11765	and	_
77-16	11766-11774	beverage	_
77-17	11775-11785	conditions	_
77-18	11786-11787	.	_

78-1	11788-11792	They	_
78-2	11793-11797	were	_
78-3	11798-11803	drawn	_
78-4	11804-11806	in	_
78-5	11807-11809	an	_
78-6	11810-11818	unbiased	_
78-7	11819-11825	manner	_
78-8	11826-11828	to	_
78-9	11829-11837	comprise	_
78-10	11838-11844	groups	_
78-11	11845-11847	of	_
78-12	11848-11855	dipoles	_
78-13	11856-11861	along	_
78-14	11862-11865	the	_
78-15	11866-11874	cortical	_
78-16	11875-11882	surface	_
78-17	11883-11887	with	_
78-18	11888-11892	most	_
78-19	11893-11900	notable	_
78-20	11901-11907	source	_
78-21	11908-11913	power	_
78-22	11914-11915	.	_

79-1	11916-11919	The	_
79-2	11920-11924	same	_
79-3	11925-11928	set	_
79-4	11929-11931	of	_
79-5	11932-11943	group-based	_
79-6	11944-11948	ROIs	_
79-7	11949-11952	was	_
79-8	11953-11957	used	_
79-9	11958-11961	for	_
79-10	11962-11965	all	_
79-11	11966-11974	subjects	_
79-12	11975-11977	in	_
79-13	11978-11979	a	_
79-14	11980-11986	manner	_
79-15	11987-11992	blind	_
79-16	11993-11995	to	_
79-17	11996-12001	their	_
79-18	12002-12012	individual	_
79-19	12013-12024	activations	_
79-20	12025-12028	via	_
79-21	12029-12038	automatic	_
79-22	12039-12047	morphing	_
79-23	12048-12049	.	_

80-1	12050-12061	Timecourses	_
80-2	12062-12065	for	_
80-3	12066-12070	each	_
80-4	12071-12074	ROI	_
80-5	12075-12079	were	_
80-6	12080-12089	extracted	_
80-7	12090-12092	by	_
80-8	12093-12102	averaging	_
80-9	12103-12107	over	_
80-10	12108-12111	all	_
80-11	12112-12120	vertices	_
80-12	12121-12129	included	_
80-13	12130-12132	in	_
80-14	12133-12136	the	_
80-15	12137-12140	ROI	_
80-16	12141-12144	and	_
80-17	12145-12148	are	_
80-18	12149-12158	presented	_
80-19	12159-12161	as	_
80-20	12162-12169	percent	_
80-21	12170-12176	change	_
80-22	12177-12181	from	_
80-23	12182-12190	baseline	_
80-24	12191-12192	.	_

81-1	12193-12196	The	_
81-2	12197-12201	ROIs	_
81-3	12202-12211	primarily	_
81-4	12212-12223	encompassed	_
81-5	12224-12227	the	_
81-6	12228-12237	cognitive	_
81-7	12238-12245	control	_
81-8	12246-12253	network	_
81-9	12254-12256	in	_
81-10	12257-12260	the	_
81-11	12261-12267	medial	_
81-12	12268-12271	and	_
81-13	12272-12279	lateral	_
81-14	12280-12287	frontal	_
81-15	12288-12295	regions	_
81-16	12296-12299	and	_
81-17	12300-12303	the	_
81-18	12304-12309	motor	_
81-19	12310-12315	areas	_
81-20	12316-12327	bilaterally	_
81-21	12328-12329	,	_
81-22	12330-12339	including	_
81-23	12340-12343	the	_
81-24	12344-12350	dorsal	_
81-25	12351-12354	ACC	_
81-26	12355-12356	,	_
81-27	12357-12374	pre-supplementary	_
81-28	12375-12380	motor	_
81-29	12381-12385	area	_
81-30	12386-12387	(	_
81-31	12388-12394	preSMA	_
81-32	12395-12396	)	_
81-33	12397-12399	on	_
81-34	12400-12403	the	_
81-35	12404-12410	medial	_
81-36	12411-12418	surface	_
81-37	12419-12420	,	_
81-38	12421-12424	the	_
81-39	12425-12433	inferior	_
81-40	12434-12441	frontal	_
81-41	12442-12448	cortex	_
81-42	12449-12450	(	_
81-43	12451-12454	IFC	_
81-44	12455-12456	)	_
81-45	12457-12458	,	_
81-46	12459-12462	and	_
81-47	12463-12475	sensorimotor	_
81-48	12476-12483	regions	_
81-49	12484-12485	(	_
81-50	12486-12490	SMOT	_
81-51	12491-12492	)	_
81-52	12493-12495	in	_
81-53	12496-12499	the	_
81-54	12500-12513	peri-Rolandic	_
81-55	12514-12518	area	_
81-56	12519-12520	,	_
81-57	12521-12523	in	_
81-58	12524-12532	addition	_
81-59	12533-12535	to	_
81-60	12536-12539	the	_
81-61	12540-12546	visual	_
81-62	12547-12551	area	_
81-63	12552-12554	in	_
81-64	12555-12558	the	_
81-65	12559-12565	medial	_
81-66	12566-12575	occipital	_
81-67	12576-12582	cortex	_
81-68	12583-12584	(	_
81-69	12585-12588	Occ	_
81-70	12589-12590	)	_
81-71	12591-12592	.	_

82-1	12593-12604	Prestimulus	_
82-2	12605-12608	raw	_
82-3	12609-12614	power	_
82-4	12615-12618	did	_
82-5	12619-12622	not	_
82-6	12623-12629	differ	_
82-7	12630-12636	across	_
82-8	12637-12647	conditions	_
82-9	12648-12650	or	_
82-10	12651-12660	beverages	_
82-11	12661-12664	for	_
82-12	12665-12671	either	_
82-13	12672-12676	beta	_
82-14	12677-12679	or	_
82-15	12680-12685	theta	_
82-16	12686-12691	bands	_
82-17	12692-12695	for	_
82-18	12696-12699	any	_
82-19	12700-12702	of	_
82-20	12703-12706	the	_
82-21	12707-12715	selected	_
82-22	12716-12720	ROIs	_
82-23	12721-12731	indicating	_
82-24	12732-12736	that	_
82-25	12737-12740	the	_
82-26	12741-12749	observed	_
82-27	12750-12763	event-related	_
82-28	12764-12771	changes	_
82-29	12772-12776	were	_
82-30	12777-12780	not	_
82-31	12781-12784	due	_
82-32	12785-12787	to	_
82-33	12788-12796	baseline	_
82-34	12797-12808	differences	_
82-35	12809-12810	.	_

83-1	12811-12825	Co-oscillatory	_
83-2	12826-12838	interactions	_
83-3	12839-12846	between	_
83-4	12847-12855	cortical	_
83-5	12856-12860	ROIs	_
83-6	12861-12865	were	_
83-7	12866-12875	estimated	_
83-8	12876-12878	by	_
83-9	12879-12890	calculating	_
83-10	12891-12904	phase-locking	_
83-11	12905-12911	values	_
83-12	12912-12913	(	_
83-13	12914-12917	PLV	_
83-14	12918-12919	)	_
83-15	12920-12921	.	_

84-1	12922-12925	PLV	_
84-2	12926-12928	is	_
84-3	12929-12930	a	_
84-4	12931-12938	measure	_
84-5	12939-12941	of	_
84-6	12942-12957	synchronization	_
84-7	12958-12962	that	_
84-8	12963-12965	is	_
84-9	12966-12975	sensitive	_
84-10	12976-12978	to	_
84-11	12979-12982	the	_
84-12	12983-12994	consistency	_
84-13	12995-12997	of	_
84-14	12998-13003	phase	_
84-15	13004-13014	difference	_
84-16	13015-13017	in	_
84-17	13018-13019	a	_
84-18	13020-13030	particular	_
84-19	13031-13040	frequency	_
84-20	13041-13046	range	_
84-21	13047-13054	between	_
84-22	13055-13058	two	_
84-23	13059-13063	ROIs	_
84-24	13064-13074	regardless	_
84-25	13075-13077	of	_
84-26	13078-13083	their	_
84-27	13084-13093	amplitude	_
84-28	13094-13095	.	_

85-1	13096-13100	Data	_
85-2	13101-13105	were	_
85-3	13106-13119	statistically	_
85-4	13120-13128	analyzed	_
85-5	13129-13135	across	_
85-6	13136-13139	all	_
85-7	13140-13144	ROIs	_
85-8	13145-13149	with	_
85-9	13150-13158	repeated	_
85-10	13159-13167	measures	_
85-11	13168-13174	ANOVAs	_
85-12	13175-13179	with	_
85-13	13180-13183	the	_
85-14	13184-13191	factors	_
85-15	13192-13194	of	_
85-16	13195-13203	Beverage	_
85-17	13204-13205	(	_
85-18	13206-13213	alcohol	_
85-19	13214-13216	vs	_
85-20	13217-13224	placebo	_
85-21	13225-13226	)	_
85-22	13227-13230	and	_
85-23	13231-13240	Condition	_
85-24	13241-13243	as	_
85-25	13244-13253	described	_
85-26	13254-13256	in	_
85-27	13257-13260	the	_
85-28	13261-13269	relevant	_
85-29	13270-13277	results	_
85-30	13278-13286	sections	_
85-31	13287-13292	below	_
85-32	13293-13294	.	_

86-1	13295-13296	A	_
86-2	13297-13309	significance	_
86-3	13310-13319	threshold	_
86-4	13320-13321	(	_
86-5	13322-13327	alpha	_
86-6	13328-13329	)	_
86-7	13330-13332	of	_
86-8	13333-13337	0.05	_
86-9	13338-13341	was	_
86-10	13342-13349	adopted	_
86-11	13350-13352	in	_
86-12	13353-13356	all	_
86-13	13357-13365	analyses	_
86-14	13366-13367	.	_

87-1	13368-13373	Bayes	_
87-2	13374-13381	factors	_
87-3	13382-13386	were	_
87-4	13387-13391	also	_
87-5	13392-13399	applied	_
87-6	13400-13402	to	_
87-7	13403-13412	determine	_
87-8	13413-13416	the	_
87-9	13417-13420	fit	_
87-10	13421-13423	of	_
87-11	13424-13427	the	_
87-12	13428-13432	data	_
87-13	13433-13438	under	_
87-14	13439-13442	the	_
87-15	13443-13447	null	_
87-16	13448-13458	hypothesis	_
87-17	13459-13465	versus	_
87-18	13466-13469	the	_
87-19	13470-13481	alternative	_
87-20	13482-13492	hypothesis	_
87-21	13493-13496	and	_
87-22	13497-13500	are	_
87-23	13501-13507	listed	_
87-24	13508-13510	as	_
87-25	13511-13513	BF	_
87-26	13514-13520	values	_
87-27	13521-13522	.	_

88-1	13523-13525	It	_
88-2	13526-13529	has	_
88-3	13530-13534	been	_
88-4	13535-13544	suggested	_
88-5	13545-13549	that	_
88-6	13550-13551	a	_
88-7	13552-13554	BF	_
88-8	13555-13560	above	_
88-9	13561-13562	3	_
88-10	13563-13572	indicates	_
88-11	13573-13584	substantial	_
88-12	13585-13592	support	_
88-13	13593-13596	for	_
88-14	13597-13600	the	_
88-15	13601-13612	alternative	_
88-16	13613-13623	hypothesis	_
88-17	13624-13625	.	_

89-1	13626-13636	Conversely	_
89-2	13637-13638	,	_
89-3	13639-13640	a	_
89-4	13641-13643	BF	_
89-5	13644-13649	below	_
89-6	13650-13654	0.33	_
89-7	13655-13663	reflects	_
89-8	13664-13671	support	_
89-9	13672-13675	for	_
89-10	13676-13679	the	_
89-11	13680-13684	null	_
89-12	13685-13695	hypothesis	_
89-13	13696-13697	.	_

